Wedbush Reaffirms Outperform Rating for Chimerix (NASDAQ:CMRX)

Wedbush restated their outperform rating on shares of Chimerix (NASDAQ:CMRX) in a research note issued to investors on Thursday morning,RTT News reports. Wedbush currently has a $6.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on CMRX. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a report on Wednesday, August 14th. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st.

Chimerix Stock Performance

NASDAQ CMRX traded up $0.10 during trading on Thursday, hitting $1.04. The stock had a trading volume of 518,836 shares, compared to its average volume of 353,017. Chimerix has a one year low of $0.75 and a one year high of $1.30. The stock has a 50 day simple moving average of $0.90 and a 200 day simple moving average of $0.91. The stock has a market capitalization of $93.23 million, a price-to-earnings ratio of -1.09 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.23). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the previous year, the firm earned ($0.21) EPS. On average, sell-side analysts predict that Chimerix will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Chimerix

Several large investors have recently modified their holdings of the business. Marshall Wace LLP bought a new position in Chimerix in the second quarter worth approximately $137,000. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 69,505 shares during the period. Acadian Asset Management LLC raised its position in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after acquiring an additional 291,981 shares in the last quarter. Finally, Koshinski Asset Management Inc. purchased a new stake in shares of Chimerix during the 1st quarter worth $42,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.